Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.

CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort. PMID: 33357641 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33357641?dopt=Abstract

Source: Indian Heart J - November 1, 2020 Category: Cardiology Authors: Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S Tags: Indian Heart J Source Type: research